January 14th, 2021
Tres Cantos, Madrid, Spain. Protein Alternatives (PROALT), a leading company in the development of therapeutic monoclonal antibodies in oncology, has been selected as one of the two companies that will receive funding from the R&D and innovation programme of Madrid Region during 2021 and 2022.
MetastCure project, with title “Preclinical evaluation of anti IL13Ra2 antibodies for the treatment of metastatic colorectal cancer”, has been selected for financing by the Counseling of Science, Universities and Innovation of Madrid Region.
The objective of the project is to obtain preclinical data on the anti-IL13Ra2 antibodies developed by the company for the treatment of liver metastasis of colorectal cancer (mCRC), a disease with few therapeutic options and poor prognosis as indicated by the high mortality rates of these patients.